20 percent more patients were treated with proton therapy in 2019
An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam. © HZB
Number of patients who received the proton therapy offered jointly by Charité and HZB. © HZB/J. Politt
For more than 20 years, Charité - Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have jointly offered the irradiation of eye tumors with protons. In 2019, more patients were treated in Berlin-Wannsee than ever before. 276 patients - 20 percent more than in the previous year - underwent proton therapy. The treatment is specialized in choroidal melanomas of the eye. The proton accelerator at HZB is the only treatment facility for this disease in Germany.
500 to 600 people in Germany are affected by a malignant choroidal melanoma every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be maintained to a satisfactory degree. "The energy of the proton beam can be adjusted in such a way that practically only the tumor receives the radiation. Since the protons have a straight trajectory, the lateral scattering is much less than with X-rays," explains Dr. Jens Heufelder, the senior medical physicist at Charité - Universitätsmedizin Berlin. The protons effectively destroy the tumor, while the surrounding healthy tissue is largely spared.
To cope with the increase in patients in 2019, treatment operations at the proton accelerator have been extended to 12 hours. Approximately 45 percent of the patients came from the Berlin-Brandenburg region, the other patients came from other German states and other European countries (approximately 8 percent). The youngest patient who received proton therapy at HZB in 2019 was 8 years old, the oldest patient 96 years old. The average age was 61 years.
Since 1998, more than 3,700 patients have been treated with protons from the HZB accelerator. "The success of proton therapy is based on the collaboration between ophthalmologists, medical physicists and accelerator experts. As a result, the therapy has been continuously improved for the benefit of patients over the past few years", explains Prof. Dr. Andrea Denker, head of proton therapy at HZB.
- More time for discussionsThe South African chemist Denzil Moodley is the first Industrial Research Fellow at HZB. He is playing a leading role in the CARE-O-SENE project. The Fellowship program aims to further accelerate the development of an efficient catalyst for a sustainable aviation fuel. An interview about the CARE-O-SENE project and why it is so important for scientists from industry and public research to work together.
- Perovskites: Hybrid materials as highly sensitive X-ray detectorsNew bismuth-based organic-inorganic hybrid materials show exceptional sensitivity and long-term stability as X-ray detectors, significantly more sensitive than commercial X-ray detectors. In addition, these materials can be produced without solvents by ball milling, a mechanochemical synthesis process that is environmentally friendly and scalable. More sensitive detectors would allow for a reduction in the radiation exposure during X-ray examinations.
- Electrical energy storage: BAM, HZB, and HU Berlin plan joint Berlin Battery LabThe Federal Institute for Materials Research and Testing (BAM), the Helmholtz-Zentrum Berlin (HZB), and Humboldt University of Berlin (HU Berlin) have signed a memorandum of understanding (MoU) to establish the Berlin Battery Lab. The lab will pool the expertise of the three institutions to advance the development of sustainable battery technologies. The joint research infrastructure will also be open to industry for pioneering projects in this field.